Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 108,366 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 108,366 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $31.73, for a total value of $3,438,453.18. Following the sale, the chief executive officer now directly owns 605,417 shares in the company, valued at approximately $19,209,881.41. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Andrew Cheng also recently made the following trade(s):

• On Friday, October 18th, Andrew Cheng sold 63,539 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.53, for a total value of $2,003,384.67.
• On Wednesday, October 16th, Andrew Cheng sold 24,992 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.14, for a total value of $778,250.88.
• On Tuesday, September 10th, Andrew Cheng sold 1,738 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total value of $45,500.84.

Akero Therapeutics Trading Up 2.2 %

AKRO opened at $32.74 on Wednesday. The firm has a market cap of $2.27 billion, a P/E ratio of -9.60 and a beta of -0.26. Akero Therapeutics, Inc. has a 12 month low of $13.39 and a 12 month high of $37.00. The company has a current ratio of 24.89, a quick ratio of 24.89 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average of $28.54 and a 200 day moving average of $24.97.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.09. As a group, research analysts forecast that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Akero Therapeutics in a research report on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $43.20.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. grew its position in Akero Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after acquiring an additional 446 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in Akero Therapeutics by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after purchasing an additional 1,030 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in Akero Therapeutics by 2,366.0% in the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after purchasing an additional 1,183 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Akero Therapeutics by 15.6% in the first quarter. Principal Financial Group Inc. now owns 13,766 shares of the company’s stock worth $348,000 after purchasing an additional 1,858 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its stake in Akero Therapeutics by 12.4% in the third quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company’s stock worth $574,000 after purchasing an additional 2,200 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.